Resumen
Treatment modalities for sarcoma have not changed significantly for the past few years despite 25?50% of patients experiencing relapse or progressing to metastatic diseases that become resistant to standard of care therapy, indicating an unmet need for better treatment strategies. While immunotherapy has shown promising results in other types of cancer such as melanoma, first generation immunotherapy trials in sarcomas patients showed unsatisfactory results. Nevertheless, the progressive deepening of our knowledge about the immune landscape of sarcomas and the consequent ability to dissect the heterogeneity of these tumours are leading to a more accurate stratification of patients to be treated with immunotherapy. In addition, new targets are being exploited by a variety of promising immunotherapeutic treatments, which are expected to considerably improve the clinical management of sarcoma patients.